MSc., PhD Candidate, TTUHSC, Egypt
Mohamed Ashraf Eltokhy is an Assistant Lecturer at the Graduate School of Biomedical Sciences at Texas Tech University Health Sciences Center (TTUHSC) in Abilene, Texas, and a PhD student specializing in Immunotherapeutic & Biotechnology. With a strong background in pharmacy and microbiology, his research is focused on cancer therapeutics, particularly in developing novel anticancer agents and advancing drug discovery mechanisms. His goal is to contribute to more effective and safer cancer treatments. Mohamed is also the CEO of Neopurpose Therapeutics, where he focuses on strategic decision-making, business development, and customer acquisition.
Profile
Orcid
📚 Education
Mohamed holds a Bachelor of Science in Pharmaceutical Science from Misr International University (MIU) in Cairo, Egypt, where he graduated with honors. He completed his MSc in Microbiology & Immunology from Al-Azhar University, also in Cairo. Currently, he is pursuing a PhD at Texas Tech University Health Sciences Center, where he maintains an impressive GPA of 3.948.
🎓 Experience
Mohamed’s career combines academic teaching and hands-on research. He serves as an Assistant Lecturer at MIU in Cairo, where he teaches microbiology, immunology, and biochemistry courses. Additionally, he is a Guest Researcher at Leiden University in the Netherlands and has worked as a pharmacist and in pharmaceutical regulatory affairs in Egypt. His work in cancer therapeutics is complemented by his leadership role as CEO of Neopurpose Therapeutics.
🧬 Research Interests
His research interests primarily focus on cancer treatment, specifically the development of novel anticancer agents and their mechanistic studies. He is also exploring the use of 3D bioprinted tumor-on-chip models for drug discovery and the individualization of chemotherapy regimens. His work includes in vitro and in vivo screening of agents and the study of their safety and efficacy.
🏆 Awards
Mohamed’s dedication to research and academic excellence has been recognized with multiple awards, including the Texas Tech Accelerator Program Award in 2024 and a late-breaking poster presentation award at the AACR conference in 2024. He has also received accolades for his contributions to the Microbiology & Immunology department at MIU, including academic excellence awards in 2021 and 2022, as well as the Top-Ranked Graduation Award in 2015 for achieving the highest GPA.
📖 Publications Top Notes
Patel, B., Silwal, A., Eltokhy, M. A., Gaikwad, S., Curcic, M., Patel, J., & Prasad, S. (2024). Deciphering CD59: Unveiling Its Role in Immune Microenvironment and Prognostic Significance. Cancers, 16(21), 3699.
Link to article
Eltokhy, M.A., Saad, B.T., Eltayeb, W.N., et al. (2024). Metagenomic nanopore sequencing for exploring the nature of antimicrobial metabolites of Bacillus haynesii. AMB Express, 14, 52.
Link to article
Eltokhy, M.A., Saad, B.T., Eltayeb, W.N., et al. (2021). Exploring the Nature of the Antimicrobial Metabolites Produced by Paenibacillus ehimensis Soil Isolate MZ921932 Using a Metagenomic Nanopore Sequencing Coupled with LC-Mass Analysis. Journal of Antibiotics (MDPI).
Link to article
Eltokhy, M.A., Saad, B.T., Eltayeb, W.N., et al. (2021). A metagenomic nanopore sequence analysis combined with conventional screening and spectroscopic methods for deciphering the antimicrobial metabolites produced by Alcaligenes faecalis soil isolate MZ921504. Journal of Antibiotics (MDPI).
Link to article
Eassa HA, Eltokhy MA, Fayyaz HA, et al. (2020). Current Topical Strategies for Skin-Aging and Inflammaging Treatment: Science versus Fiction. Europe PMC.
Link to article
Conclusion
In conclusion, Mohamed Ashraf Eltokhy is a highly deserving candidate for the Best Researcher Award, given his consistent dedication to advancing cancer research and his ongoing contributions to drug discovery. His work holds immense potential for improving cancer treatments and diagnostics, and with further growth in bioinformatics and clinical research, his impact on the field will undoubtedly increase. His leadership in both academic and entrepreneurial settings reflects his commitment to translating research into real-world applications.